nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—HRH1—atherosclerosis	0.65	1	CbGaD
Olopatadine—CYP3A4—Rosuvastatin—atherosclerosis	0.0159	0.211	CbGbCtD
Olopatadine—CYP3A4—Ezetimibe—atherosclerosis	0.0159	0.211	CbGbCtD
Olopatadine—CYP3A4—Simvastatin—atherosclerosis	0.0148	0.196	CbGbCtD
Olopatadine—CYP3A4—Lovastatin—atherosclerosis	0.0145	0.192	CbGbCtD
Olopatadine—CYP3A4—Pravastatin—atherosclerosis	0.0145	0.192	CbGbCtD
Olopatadine—S100B—artery—atherosclerosis	0.00882	0.139	CbGeAlD
Olopatadine—S100B—blood vessel—atherosclerosis	0.00687	0.108	CbGeAlD
Olopatadine—Skin burning sensation—Niacin—atherosclerosis	0.00509	0.048	CcSEcCtD
Olopatadine—S100A1—connective tissue—atherosclerosis	0.00408	0.0642	CbGeAlD
Olopatadine—S100A13—connective tissue—atherosclerosis	0.00362	0.0569	CbGeAlD
Olopatadine—S100A12—connective tissue—atherosclerosis	0.00357	0.0562	CbGeAlD
Olopatadine—S100A1—cardiovascular system—atherosclerosis	0.00355	0.0558	CbGeAlD
Olopatadine—S100B—connective tissue—atherosclerosis	0.00352	0.0554	CbGeAlD
Olopatadine—S100A2—adipose tissue—atherosclerosis	0.0034	0.0535	CbGeAlD
Olopatadine—S100A13—cardiovascular system—atherosclerosis	0.00315	0.0495	CbGeAlD
Olopatadine—S100A1—adipose tissue—atherosclerosis	0.00313	0.0492	CbGeAlD
Olopatadine—S100A12—cardiovascular system—atherosclerosis	0.00311	0.0489	CbGeAlD
Olopatadine—S100B—cardiovascular system—atherosclerosis	0.00306	0.0482	CbGeAlD
Olopatadine—S100A13—adipose tissue—atherosclerosis	0.00278	0.0437	CbGeAlD
Olopatadine—S100A12—adipose tissue—atherosclerosis	0.00274	0.0431	CbGeAlD
Olopatadine—S100B—adipose tissue—atherosclerosis	0.0027	0.0425	CbGeAlD
Olopatadine—Endophthalmitis—Pravastatin—atherosclerosis	0.00257	0.0242	CcSEcCtD
Olopatadine—S100A13—liver—atherosclerosis	0.00195	0.0306	CbGeAlD
Olopatadine—S100A12—liver—atherosclerosis	0.00192	0.0302	CbGeAlD
Olopatadine—Cough increased—Rosuvastatin—atherosclerosis	0.00186	0.0176	CcSEcCtD
Olopatadine—Eye irritation—Lovastatin—atherosclerosis	0.00169	0.016	CcSEcCtD
Olopatadine—Cough increased—Niacin—atherosclerosis	0.00136	0.0128	CcSEcCtD
Olopatadine—Dermatitis contact—Niacin—atherosclerosis	0.00123	0.0116	CcSEcCtD
Olopatadine—Influenza—Rosuvastatin—atherosclerosis	0.00107	0.0101	CcSEcCtD
Olopatadine—Dimetindene—HRH1—atherosclerosis	0.00105	0.239	CrCbGaD
Olopatadine—Depression—Rosuvastatin—atherosclerosis	0.000952	0.00898	CcSEcCtD
Olopatadine—Urinary tract infection—Rosuvastatin—atherosclerosis	0.000928	0.00875	CcSEcCtD
Olopatadine—Nasopharyngitis—Ezetimibe—atherosclerosis	0.000921	0.00868	CcSEcCtD
Olopatadine—Influenza—Lovastatin—atherosclerosis	0.000908	0.00856	CcSEcCtD
Olopatadine—Sinusitis—Rosuvastatin—atherosclerosis	0.000896	0.00845	CcSEcCtD
Olopatadine—Influenza—Ezetimibe—atherosclerosis	0.00089	0.00839	CcSEcCtD
Olopatadine—Rhinitis—Rosuvastatin—atherosclerosis	0.00086	0.0081	CcSEcCtD
Olopatadine—Pharyngitis—Rosuvastatin—atherosclerosis	0.000851	0.00802	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000827	0.0078	CcSEcCtD
Olopatadine—Dry skin—Niacin—atherosclerosis	0.000827	0.0078	CcSEcCtD
Olopatadine—Dry skin—Pravastatin—atherosclerosis	0.000814	0.00768	CcSEcCtD
Olopatadine—Nasopharyngitis—Pravastatin—atherosclerosis	0.000794	0.00749	CcSEcCtD
Olopatadine—Infestation—Ezetimibe—atherosclerosis	0.000794	0.00748	CcSEcCtD
Olopatadine—Infestation NOS—Ezetimibe—atherosclerosis	0.000794	0.00748	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000789	0.00744	CcSEcCtD
Olopatadine—Urinary tract infection—Lovastatin—atherosclerosis	0.000787	0.00742	CcSEcCtD
Olopatadine—Influenza—Niacin—atherosclerosis	0.00078	0.00735	CcSEcCtD
Olopatadine—Influenza—Pravastatin—atherosclerosis	0.000768	0.00724	CcSEcCtD
Olopatadine—Sinusitis—Lovastatin—atherosclerosis	0.000759	0.00716	CcSEcCtD
Olopatadine—Depression—Simvastatin—atherosclerosis	0.000755	0.00712	CcSEcCtD
Olopatadine—Sinusitis—Ezetimibe—atherosclerosis	0.000745	0.00702	CcSEcCtD
Olopatadine—HRH1—connective tissue—atherosclerosis	0.000722	0.0114	CbGeAlD
Olopatadine—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000713	0.00673	CcSEcCtD
Olopatadine—Sinusitis—Simvastatin—atherosclerosis	0.00071	0.0067	CcSEcCtD
Olopatadine—Pharyngitis—Ezetimibe—atherosclerosis	0.000707	0.00667	CcSEcCtD
Olopatadine—Weight increased—Pravastatin—atherosclerosis	0.000699	0.00659	CcSEcCtD
Olopatadine—Depression—Pravastatin—atherosclerosis	0.000682	0.00643	CcSEcCtD
Olopatadine—Urinary tract infection—Pravastatin—atherosclerosis	0.000665	0.00627	CcSEcCtD
Olopatadine—Cough—Rosuvastatin—atherosclerosis	0.000651	0.00614	CcSEcCtD
Olopatadine—Immune system disorder—Ezetimibe—atherosclerosis	0.000644	0.00607	CcSEcCtD
Olopatadine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000642	0.00606	CcSEcCtD
Olopatadine—Sinusitis—Pravastatin—atherosclerosis	0.000642	0.00605	CcSEcCtD
Olopatadine—Thiothixene—HRH1—atherosclerosis	0.000634	0.144	CrCbGaD
Olopatadine—Rhinitis—Niacin—atherosclerosis	0.000626	0.0059	CcSEcCtD
Olopatadine—Hypoaesthesia—Niacin—atherosclerosis	0.000621	0.00585	CcSEcCtD
Olopatadine—Erythema—Ezetimibe—atherosclerosis	0.00062	0.00585	CcSEcCtD
Olopatadine—Dysgeusia—Lovastatin—atherosclerosis	0.000619	0.00584	CcSEcCtD
Olopatadine—Rhinitis—Pravastatin—atherosclerosis	0.000616	0.00581	CcSEcCtD
Olopatadine—Back pain—Lovastatin—atherosclerosis	0.000612	0.00577	CcSEcCtD
Olopatadine—Hypoaesthesia—Pravastatin—atherosclerosis	0.000611	0.00576	CcSEcCtD
Olopatadine—Pharyngitis—Pravastatin—atherosclerosis	0.00061	0.00575	CcSEcCtD
Olopatadine—Muscle spasms—Lovastatin—atherosclerosis	0.000608	0.00573	CcSEcCtD
Olopatadine—Infection—Rosuvastatin—atherosclerosis	0.000605	0.00571	CcSEcCtD
Olopatadine—Visual impairment—Niacin—atherosclerosis	0.000601	0.00567	CcSEcCtD
Olopatadine—Back pain—Ezetimibe—atherosclerosis	0.0006	0.00566	CcSEcCtD
Olopatadine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000597	0.00563	CcSEcCtD
Olopatadine—Muscle spasms—Ezetimibe—atherosclerosis	0.000596	0.00562	CcSEcCtD
Olopatadine—Vision blurred—Lovastatin—atherosclerosis	0.000596	0.00562	CcSEcCtD
Olopatadine—Visual impairment—Pravastatin—atherosclerosis	0.000592	0.00558	CcSEcCtD
Olopatadine—Erythema—Simvastatin—atherosclerosis	0.000592	0.00558	CcSEcCtD
Olopatadine—Ill-defined disorder—Lovastatin—atherosclerosis	0.000587	0.00553	CcSEcCtD
Olopatadine—Eye disorder—Niacin—atherosclerosis	0.000583	0.0055	CcSEcCtD
Olopatadine—Dysgeusia—Simvastatin—atherosclerosis	0.000579	0.00546	CcSEcCtD
Olopatadine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000576	0.00543	CcSEcCtD
Olopatadine—Malaise—Lovastatin—atherosclerosis	0.00057	0.00538	CcSEcCtD
Olopatadine—Muscle spasms—Simvastatin—atherosclerosis	0.000569	0.00536	CcSEcCtD
Olopatadine—Malaise—Ezetimibe—atherosclerosis	0.000559	0.00527	CcSEcCtD
Olopatadine—Vision blurred—Simvastatin—atherosclerosis	0.000558	0.00526	CcSEcCtD
Olopatadine—HRH1—adipose tissue—atherosclerosis	0.000554	0.00872	CbGeAlD
Olopatadine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000549	0.00518	CcSEcCtD
Olopatadine—Erythema—Niacin—atherosclerosis	0.000543	0.00512	CcSEcCtD
Olopatadine—Cough—Ezetimibe—atherosclerosis	0.000541	0.0051	CcSEcCtD
Olopatadine—Malaise—Simvastatin—atherosclerosis	0.000534	0.00503	CcSEcCtD
Olopatadine—Discomfort—Lovastatin—atherosclerosis	0.000532	0.00502	CcSEcCtD
Olopatadine—Dry mouth—Lovastatin—atherosclerosis	0.000527	0.00497	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000525	0.00495	CcSEcCtD
Olopatadine—Dysgeusia—Pravastatin—atherosclerosis	0.000524	0.00494	CcSEcCtD
Olopatadine—Muscle spasms—Niacin—atherosclerosis	0.000522	0.00492	CcSEcCtD
Olopatadine—Discomfort—Ezetimibe—atherosclerosis	0.000522	0.00492	CcSEcCtD
Olopatadine—Pain—Rosuvastatin—atherosclerosis	0.000521	0.00491	CcSEcCtD
Olopatadine—Dry mouth—Ezetimibe—atherosclerosis	0.000517	0.00487	CcSEcCtD
Olopatadine—Muscle spasms—Pravastatin—atherosclerosis	0.000514	0.00485	CcSEcCtD
Olopatadine—Infection—Lovastatin—atherosclerosis	0.000513	0.00483	CcSEcCtD
Olopatadine—Vision blurred—Niacin—atherosclerosis	0.000512	0.00483	CcSEcCtD
Olopatadine—Vision blurred—Pravastatin—atherosclerosis	0.000504	0.00475	CcSEcCtD
Olopatadine—Infection—Ezetimibe—atherosclerosis	0.000503	0.00474	CcSEcCtD
Olopatadine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000502	0.00473	CcSEcCtD
Olopatadine—Chlorprothixene—HRH1—atherosclerosis	0.000499	0.113	CrCbGaD
Olopatadine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000498	0.0047	CcSEcCtD
Olopatadine—Discomfort—Simvastatin—atherosclerosis	0.000498	0.00469	CcSEcCtD
Olopatadine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000497	0.00468	CcSEcCtD
Olopatadine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000496	0.00468	CcSEcCtD
Olopatadine—Skin disorder—Ezetimibe—atherosclerosis	0.000492	0.00464	CcSEcCtD
Olopatadine—Nortriptyline—HRH1—atherosclerosis	0.00049	0.111	CrCbGaD
Olopatadine—Oedema—Simvastatin—atherosclerosis	0.000483	0.00455	CcSEcCtD
Olopatadine—Malaise—Pravastatin—atherosclerosis	0.000482	0.00455	CcSEcCtD
Olopatadine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000482	0.00454	CcSEcCtD
Olopatadine—Infection—Simvastatin—atherosclerosis	0.00048	0.00452	CcSEcCtD
Olopatadine—Cough—Niacin—atherosclerosis	0.000474	0.00447	CcSEcCtD
Olopatadine—Cough—Pravastatin—atherosclerosis	0.000467	0.0044	CcSEcCtD
Olopatadine—Dyspnoea—Lovastatin—atherosclerosis	0.00046	0.00434	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000459	0.00433	CcSEcCtD
Olopatadine—Dry mouth—Niacin—atherosclerosis	0.000452	0.00426	CcSEcCtD
Olopatadine—Dyspnoea—Ezetimibe—atherosclerosis	0.000451	0.00426	CcSEcCtD
Olopatadine—Discomfort—Pravastatin—atherosclerosis	0.00045	0.00424	CcSEcCtD
Olopatadine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000449	0.00423	CcSEcCtD
Olopatadine—Fatigue—Lovastatin—atherosclerosis	0.000445	0.0042	CcSEcCtD
Olopatadine—Oedema—Niacin—atherosclerosis	0.000443	0.00418	CcSEcCtD
Olopatadine—Pain—Lovastatin—atherosclerosis	0.000441	0.00416	CcSEcCtD
Olopatadine—Doxepin—HRH1—atherosclerosis	0.000439	0.0998	CrCbGaD
Olopatadine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000437	0.00412	CcSEcCtD
Olopatadine—Asthenia—Rosuvastatin—atherosclerosis	0.000437	0.00412	CcSEcCtD
Olopatadine—Oedema—Pravastatin—atherosclerosis	0.000437	0.00412	CcSEcCtD
Olopatadine—Fatigue—Ezetimibe—atherosclerosis	0.000437	0.00412	CcSEcCtD
Olopatadine—Infection—Pravastatin—atherosclerosis	0.000434	0.00409	CcSEcCtD
Olopatadine—Pain—Ezetimibe—atherosclerosis	0.000433	0.00408	CcSEcCtD
Olopatadine—Pruritus—Rosuvastatin—atherosclerosis	0.000431	0.00406	CcSEcCtD
Olopatadine—Skin disorder—Niacin—atherosclerosis	0.000431	0.00406	CcSEcCtD
Olopatadine—Dyspnoea—Simvastatin—atherosclerosis	0.00043	0.00406	CcSEcCtD
Olopatadine—Feeling abnormal—Lovastatin—atherosclerosis	0.000425	0.00401	CcSEcCtD
Olopatadine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000422	0.00398	CcSEcCtD
Olopatadine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000417	0.00393	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000417	0.00393	CcSEcCtD
Olopatadine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000417	0.00393	CcSEcCtD
Olopatadine—Fatigue—Simvastatin—atherosclerosis	0.000416	0.00392	CcSEcCtD
Olopatadine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000414	0.0039	CcSEcCtD
Olopatadine—Pain—Simvastatin—atherosclerosis	0.000413	0.00389	CcSEcCtD
Olopatadine—Body temperature increased—Lovastatin—atherosclerosis	0.000408	0.00385	CcSEcCtD
Olopatadine—Abdominal pain—Lovastatin—atherosclerosis	0.000408	0.00385	CcSEcCtD
Olopatadine—Dizziness—Rosuvastatin—atherosclerosis	0.000403	0.0038	CcSEcCtD
Olopatadine—Body temperature increased—Ezetimibe—atherosclerosis	0.0004	0.00377	CcSEcCtD
Olopatadine—Abdominal pain—Ezetimibe—atherosclerosis	0.0004	0.00377	CcSEcCtD
Olopatadine—Feeling abnormal—Simvastatin—atherosclerosis	0.000398	0.00375	CcSEcCtD
Olopatadine—Dyspnoea—Niacin—atherosclerosis	0.000395	0.00373	CcSEcCtD
Olopatadine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000395	0.00372	CcSEcCtD
Olopatadine—Somnolence—Niacin—atherosclerosis	0.000394	0.00372	CcSEcCtD
Olopatadine—Dyspnoea—Pravastatin—atherosclerosis	0.000389	0.00367	CcSEcCtD
Olopatadine—Rash—Rosuvastatin—atherosclerosis	0.000384	0.00362	CcSEcCtD
Olopatadine—Dermatitis—Rosuvastatin—atherosclerosis	0.000384	0.00362	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000383	0.00361	CcSEcCtD
Olopatadine—Abdominal pain—Simvastatin—atherosclerosis	0.000382	0.0036	CcSEcCtD
Olopatadine—Body temperature increased—Simvastatin—atherosclerosis	0.000382	0.0036	CcSEcCtD
Olopatadine—Headache—Rosuvastatin—atherosclerosis	0.000382	0.0036	CcSEcCtD
Olopatadine—Hypersensitivity—Lovastatin—atherosclerosis	0.00038	0.00359	CcSEcCtD
Olopatadine—Pain—Niacin—atherosclerosis	0.000379	0.00357	CcSEcCtD
Olopatadine—Fatigue—Pravastatin—atherosclerosis	0.000376	0.00355	CcSEcCtD
Olopatadine—Pain—Pravastatin—atherosclerosis	0.000373	0.00352	CcSEcCtD
Olopatadine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000373	0.00352	CcSEcCtD
Olopatadine—Asthenia—Lovastatin—atherosclerosis	0.00037	0.00349	CcSEcCtD
Olopatadine—Pruritus—Lovastatin—atherosclerosis	0.000365	0.00344	CcSEcCtD
Olopatadine—Asthenia—Ezetimibe—atherosclerosis	0.000363	0.00342	CcSEcCtD
Olopatadine—Gastrointestinal pain—Niacin—atherosclerosis	0.000363	0.00342	CcSEcCtD
Olopatadine—Nausea—Rosuvastatin—atherosclerosis	0.000362	0.00341	CcSEcCtD
Olopatadine—Feeling abnormal—Pravastatin—atherosclerosis	0.00036	0.00339	CcSEcCtD
Olopatadine—Pruritus—Ezetimibe—atherosclerosis	0.000358	0.00338	CcSEcCtD
Olopatadine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000357	0.00337	CcSEcCtD
Olopatadine—Hypersensitivity—Simvastatin—atherosclerosis	0.000356	0.00335	CcSEcCtD
Olopatadine—Diarrhoea—Lovastatin—atherosclerosis	0.000353	0.00333	CcSEcCtD
Olopatadine—Abdominal pain—Niacin—atherosclerosis	0.00035	0.0033	CcSEcCtD
Olopatadine—Body temperature increased—Niacin—atherosclerosis	0.00035	0.0033	CcSEcCtD
Olopatadine—Asthenia—Simvastatin—atherosclerosis	0.000346	0.00327	CcSEcCtD
Olopatadine—Diarrhoea—Ezetimibe—atherosclerosis	0.000346	0.00327	CcSEcCtD
Olopatadine—Body temperature increased—Pravastatin—atherosclerosis	0.000345	0.00325	CcSEcCtD
Olopatadine—Abdominal pain—Pravastatin—atherosclerosis	0.000345	0.00325	CcSEcCtD
Olopatadine—Imipramine—HRH1—atherosclerosis	0.000342	0.0776	CrCbGaD
Olopatadine—Pruritus—Simvastatin—atherosclerosis	0.000342	0.00322	CcSEcCtD
Olopatadine—Dizziness—Lovastatin—atherosclerosis	0.000341	0.00322	CcSEcCtD
Olopatadine—Amitriptyline—HRH1—atherosclerosis	0.00034	0.0772	CrCbGaD
Olopatadine—Dizziness—Ezetimibe—atherosclerosis	0.000335	0.00316	CcSEcCtD
Olopatadine—Diarrhoea—Simvastatin—atherosclerosis	0.00033	0.00311	CcSEcCtD
Olopatadine—Vomiting—Lovastatin—atherosclerosis	0.000328	0.00309	CcSEcCtD
Olopatadine—Hypersensitivity—Niacin—atherosclerosis	0.000327	0.00308	CcSEcCtD
Olopatadine—Rash—Lovastatin—atherosclerosis	0.000325	0.00307	CcSEcCtD
Olopatadine—Dermatitis—Lovastatin—atherosclerosis	0.000325	0.00307	CcSEcCtD
Olopatadine—Headache—Lovastatin—atherosclerosis	0.000323	0.00305	CcSEcCtD
Olopatadine—Vomiting—Ezetimibe—atherosclerosis	0.000322	0.00304	CcSEcCtD
Olopatadine—Hypersensitivity—Pravastatin—atherosclerosis	0.000322	0.00303	CcSEcCtD
Olopatadine—Dizziness—Simvastatin—atherosclerosis	0.000319	0.00301	CcSEcCtD
Olopatadine—Rash—Ezetimibe—atherosclerosis	0.000319	0.00301	CcSEcCtD
Olopatadine—Dermatitis—Ezetimibe—atherosclerosis	0.000319	0.00301	CcSEcCtD
Olopatadine—Asthenia—Niacin—atherosclerosis	0.000318	0.003	CcSEcCtD
Olopatadine—Headache—Ezetimibe—atherosclerosis	0.000317	0.00299	CcSEcCtD
Olopatadine—Pruritus—Niacin—atherosclerosis	0.000314	0.00296	CcSEcCtD
Olopatadine—Asthenia—Pravastatin—atherosclerosis	0.000313	0.00295	CcSEcCtD
Olopatadine—Pruritus—Pravastatin—atherosclerosis	0.000309	0.00291	CcSEcCtD
Olopatadine—Vomiting—Simvastatin—atherosclerosis	0.000307	0.00289	CcSEcCtD
Olopatadine—Nausea—Lovastatin—atherosclerosis	0.000307	0.00289	CcSEcCtD
Olopatadine—Rash—Simvastatin—atherosclerosis	0.000304	0.00287	CcSEcCtD
Olopatadine—Dermatitis—Simvastatin—atherosclerosis	0.000304	0.00287	CcSEcCtD
Olopatadine—Diarrhoea—Niacin—atherosclerosis	0.000303	0.00286	CcSEcCtD
Olopatadine—Headache—Simvastatin—atherosclerosis	0.000302	0.00285	CcSEcCtD
Olopatadine—Nausea—Ezetimibe—atherosclerosis	0.000301	0.00284	CcSEcCtD
Olopatadine—CYP3A4—liver—atherosclerosis	0.000301	0.00473	CbGeAlD
Olopatadine—Diarrhoea—Pravastatin—atherosclerosis	0.000299	0.00282	CcSEcCtD
Olopatadine—Dizziness—Niacin—atherosclerosis	0.000293	0.00276	CcSEcCtD
Olopatadine—Dizziness—Pravastatin—atherosclerosis	0.000289	0.00272	CcSEcCtD
Olopatadine—Nausea—Simvastatin—atherosclerosis	0.000287	0.0027	CcSEcCtD
Olopatadine—Vomiting—Niacin—atherosclerosis	0.000282	0.00266	CcSEcCtD
Olopatadine—Rash—Niacin—atherosclerosis	0.00028	0.00264	CcSEcCtD
Olopatadine—Dermatitis—Niacin—atherosclerosis	0.000279	0.00263	CcSEcCtD
Olopatadine—Headache—Niacin—atherosclerosis	0.000278	0.00262	CcSEcCtD
Olopatadine—Vomiting—Pravastatin—atherosclerosis	0.000278	0.00262	CcSEcCtD
Olopatadine—Rash—Pravastatin—atherosclerosis	0.000275	0.00259	CcSEcCtD
Olopatadine—Dermatitis—Pravastatin—atherosclerosis	0.000275	0.00259	CcSEcCtD
Olopatadine—Headache—Pravastatin—atherosclerosis	0.000273	0.00258	CcSEcCtD
Olopatadine—Nausea—Niacin—atherosclerosis	0.000263	0.00248	CcSEcCtD
Olopatadine—Nausea—Pravastatin—atherosclerosis	0.000259	0.00244	CcSEcCtD
Olopatadine—Acepromazine—ALB—atherosclerosis	0.000152	0.0346	CrCbGaD
Olopatadine—Thiothixene—ALB—atherosclerosis	0.000146	0.0332	CrCbGaD
Olopatadine—Clomipramine—ALB—atherosclerosis	0.000116	0.0263	CrCbGaD
Olopatadine—Nortriptyline—ALB—atherosclerosis	0.000113	0.0257	CrCbGaD
Olopatadine—Amitriptyline—ALB—atherosclerosis	7.85e-05	0.0178	CrCbGaD
Olopatadine—S100B—Immune System—AGER—atherosclerosis	5.65e-05	0.000562	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NCF1—atherosclerosis	5.63e-05	0.00056	CbGpPWpGaD
Olopatadine—S100B—Immune System—PRKCG—atherosclerosis	5.6e-05	0.000556	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	5.51e-05	0.000547	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	5.47e-05	0.000544	CbGpPWpGaD
Olopatadine—S100B—Immune System—CD36—atherosclerosis	5.47e-05	0.000543	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CCL3—atherosclerosis	5.42e-05	0.000538	CbGpPWpGaD
Olopatadine—HRH1—G alpha (q) signalling events—F2—atherosclerosis	5.37e-05	0.000534	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PDGFB—atherosclerosis	5.33e-05	0.00053	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EDNRA—atherosclerosis	5.32e-05	0.000529	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCR2—atherosclerosis	5.32e-05	0.000529	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—AKT1—atherosclerosis	5.3e-05	0.000527	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CYBA—atherosclerosis	5.3e-05	0.000526	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CRP—atherosclerosis	5.21e-05	0.000518	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—NFKB1—atherosclerosis	5.21e-05	0.000518	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	5.2e-05	0.000517	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PLAT—atherosclerosis	5.19e-05	0.000515	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PARP1—atherosclerosis	5.19e-05	0.000515	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—GHRL—atherosclerosis	5.19e-05	0.000515	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—MAPK8—atherosclerosis	5.12e-05	0.000509	CbGpPWpGaD
Olopatadine—S100B—Immune System—PDGFB—atherosclerosis	5.04e-05	0.000501	CbGpPWpGaD
Olopatadine—S100A12—Immune System—TLR4—atherosclerosis	5e-05	0.000497	CbGpPWpGaD
Olopatadine—S100B—Immune System—CRP—atherosclerosis	4.93e-05	0.00049	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—NFKB1—atherosclerosis	4.93e-05	0.000489	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CCR2—atherosclerosis	4.9e-05	0.000487	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—EDNRA—atherosclerosis	4.9e-05	0.000487	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—MAPK8—atherosclerosis	4.84e-05	0.000481	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	4.81e-05	0.000477	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ICAM1—atherosclerosis	4.79e-05	0.000476	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—GHRL—atherosclerosis	4.78e-05	0.000475	CbGpPWpGaD
Olopatadine—S100B—Immune System—TLR4—atherosclerosis	4.73e-05	0.00047	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	4.64e-05	0.000461	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	4.6e-05	0.000457	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KNG1—atherosclerosis	4.55e-05	0.000452	CbGpPWpGaD
Olopatadine—S100B—Immune System—ICAM1—atherosclerosis	4.53e-05	0.00045	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AGTR1—atherosclerosis	4.52e-05	0.000449	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—MAPK3—atherosclerosis	4.47e-05	0.000444	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PLG—atherosclerosis	4.41e-05	0.000438	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—MAPK3—atherosclerosis	4.23e-05	0.00042	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—KNG1—atherosclerosis	4.19e-05	0.000417	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SOCS3—atherosclerosis	4.18e-05	0.000415	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—AGTR1—atherosclerosis	4.17e-05	0.000414	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CCL4—atherosclerosis	4.07e-05	0.000404	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MMP3—atherosclerosis	4.03e-05	0.000401	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IGF2—atherosclerosis	4.02e-05	0.000399	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—UTS2—atherosclerosis	4e-05	0.000397	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—APOB—atherosclerosis	3.9e-05	0.000387	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	3.85e-05	0.000383	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EDN1—atherosclerosis	3.84e-05	0.000381	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CASR—atherosclerosis	3.83e-05	0.000381	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCL5—atherosclerosis	3.81e-05	0.000378	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—LPL—atherosclerosis	3.72e-05	0.00037	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IFNG—atherosclerosis	3.65e-05	0.000362	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—UTS2—atherosclerosis	3.63e-05	0.000361	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PRKCG—atherosclerosis	3.62e-05	0.000359	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CNR2—atherosclerosis	3.56e-05	0.000354	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	3.56e-05	0.000354	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—EDN1—atherosclerosis	3.53e-05	0.000351	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SPP1—atherosclerosis	3.52e-05	0.00035	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CCL5—atherosclerosis	3.51e-05	0.000348	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CX3CR1—atherosclerosis	3.48e-05	0.000346	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CASR—atherosclerosis	3.48e-05	0.000346	CbGpPWpGaD
Olopatadine—S100B—Immune System—IFNG—atherosclerosis	3.45e-05	0.000343	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CX3CL1—atherosclerosis	3.41e-05	0.000339	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IL6—atherosclerosis	3.27e-05	0.000325	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PDGFB—atherosclerosis	3.26e-05	0.000324	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL1B—atherosclerosis	3.25e-05	0.000323	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CNR2—atherosclerosis	3.23e-05	0.000321	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AGT—atherosclerosis	3.18e-05	0.000316	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	3.17e-05	0.000315	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—LEP—atherosclerosis	3.12e-05	0.00031	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—APOE—atherosclerosis	3.12e-05	0.00031	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IL6—atherosclerosis	3.09e-05	0.000307	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CAV1—atherosclerosis	3.09e-05	0.000307	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—APOA1—atherosclerosis	3.08e-05	0.000306	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL1B—atherosclerosis	3.08e-05	0.000306	CbGpPWpGaD
Olopatadine—S100A12—Immune System—NFKB1—atherosclerosis	3.03e-05	0.000301	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—AKT1—atherosclerosis	3.02e-05	0.0003	CbGpPWpGaD
Olopatadine—S100A12—Immune System—MAPK8—atherosclerosis	2.98e-05	0.000296	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ESR1—atherosclerosis	2.98e-05	0.000296	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—F2—atherosclerosis	2.94e-05	0.000292	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—AGT—atherosclerosis	2.93e-05	0.000291	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	2.88e-05	0.000286	CbGpPWpGaD
Olopatadine—S100B—Immune System—NFKB1—atherosclerosis	2.87e-05	0.000285	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—AKT1—atherosclerosis	2.85e-05	0.000283	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	2.84e-05	0.000282	CbGpPWpGaD
Olopatadine—S100B—Immune System—MAPK8—atherosclerosis	2.82e-05	0.00028	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CG—atherosclerosis	2.82e-05	0.00028	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CCL3—atherosclerosis	2.78e-05	0.000276	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—EDNRA—atherosclerosis	2.77e-05	0.000275	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CCR2—atherosclerosis	2.77e-05	0.000275	CbGpPWpGaD
Olopatadine—S100A12—Immune System—STAT3—atherosclerosis	2.73e-05	0.000271	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—F2—atherosclerosis	2.71e-05	0.000269	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—GHRL—atherosclerosis	2.7e-05	0.000268	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—INS—atherosclerosis	2.67e-05	0.000265	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCL2—atherosclerosis	2.62e-05	0.00026	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—APOA4—atherosclerosis	2.61e-05	0.000259	CbGpPWpGaD
Olopatadine—S100A12—Immune System—MAPK3—atherosclerosis	2.61e-05	0.000259	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	2.6e-05	0.000258	CbGpPWpGaD
Olopatadine—S100B—Immune System—STAT3—atherosclerosis	2.58e-05	0.000256	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IGF1—atherosclerosis	2.58e-05	0.000256	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CCR2—atherosclerosis	2.52e-05	0.00025	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—EDNRA—atherosclerosis	2.52e-05	0.00025	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	2.51e-05	0.000249	CbGpPWpGaD
Olopatadine—S100B—Immune System—MAPK3—atherosclerosis	2.46e-05	0.000245	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—GHRL—atherosclerosis	2.45e-05	0.000244	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SERPINE1—atherosclerosis	2.45e-05	0.000243	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CCL2—atherosclerosis	2.42e-05	0.00024	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCL4—atherosclerosis	2.41e-05	0.000239	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—KNG1—atherosclerosis	2.37e-05	0.000235	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—AGTR1—atherosclerosis	2.36e-05	0.000234	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NOS3—atherosclerosis	2.34e-05	0.000232	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—APOA2—atherosclerosis	2.25e-05	0.000223	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—KNG1—atherosclerosis	2.15e-05	0.000214	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—UTS2—atherosclerosis	2.14e-05	0.000213	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AGTR1—atherosclerosis	2.14e-05	0.000212	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CXCL8—atherosclerosis	2.07e-05	0.000206	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CX3CR1—atherosclerosis	2.06e-05	0.000204	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CASR—atherosclerosis	2.06e-05	0.000204	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	2.04e-05	0.000203	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CX3CL1—atherosclerosis	2.02e-05	0.0002	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—EDN1—atherosclerosis	2e-05	0.000198	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CCL5—atherosclerosis	1.98e-05	0.000197	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PLTP—atherosclerosis	1.92e-05	0.00019	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CNR2—atherosclerosis	1.91e-05	0.00019	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CXCL8—atherosclerosis	1.91e-05	0.00019	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—MMP3—atherosclerosis	1.91e-05	0.000189	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL6—atherosclerosis	1.9e-05	0.000189	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	1.9e-05	0.000189	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PRKCG—atherosclerosis	1.88e-05	0.000187	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MMP9—atherosclerosis	1.88e-05	0.000186	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NFKB1—atherosclerosis	1.86e-05	0.000184	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MAPK8—atherosclerosis	1.82e-05	0.000181	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—EDN1—atherosclerosis	1.81e-05	0.00018	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL6—atherosclerosis	1.8e-05	0.000179	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CCL5—atherosclerosis	1.8e-05	0.000179	CbGpPWpGaD
Olopatadine—S100A12—Immune System—AKT1—atherosclerosis	1.76e-05	0.000175	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PRKCG—atherosclerosis	1.71e-05	0.00017	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VWF—atherosclerosis	1.7e-05	0.000169	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—APOC3—atherosclerosis	1.69e-05	0.000168	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—VEGFA—atherosclerosis	1.68e-05	0.000167	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LDLR—atherosclerosis	1.68e-05	0.000167	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—STAT3—atherosclerosis	1.67e-05	0.000166	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCG8—atherosclerosis	1.66e-05	0.000165	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LTA4H—atherosclerosis	1.66e-05	0.000165	CbGpPWpGaD
Olopatadine—S100B—Immune System—AKT1—atherosclerosis	1.66e-05	0.000165	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—AGT—atherosclerosis	1.66e-05	0.000165	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCL3—atherosclerosis	1.64e-05	0.000163	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MAPK3—atherosclerosis	1.59e-05	0.000158	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NCF1—atherosclerosis	1.57e-05	0.000156	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TGFB1—atherosclerosis	1.55e-05	0.000154	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—F2—atherosclerosis	1.53e-05	0.000152	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AGT—atherosclerosis	1.51e-05	0.00015	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCR2—atherosclerosis	1.49e-05	0.000148	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EDNRA—atherosclerosis	1.49e-05	0.000148	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CYBA—atherosclerosis	1.48e-05	0.000147	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CG—atherosclerosis	1.47e-05	0.000146	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PARP1—atherosclerosis	1.45e-05	0.000144	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GHRL—atherosclerosis	1.45e-05	0.000144	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PLAT—atherosclerosis	1.45e-05	0.000144	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—F2—atherosclerosis	1.39e-05	0.000138	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CG—atherosclerosis	1.33e-05	0.000132	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.31e-05	0.000131	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KNG1—atherosclerosis	1.27e-05	0.000126	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AGTR1—atherosclerosis	1.26e-05	0.000126	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CCL2—atherosclerosis	1.24e-05	0.000123	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—FABP4—atherosclerosis	1.24e-05	0.000123	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LCAT—atherosclerosis	1.24e-05	0.000123	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PLG—atherosclerosis	1.23e-05	0.000122	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—APOA4—atherosclerosis	1.21e-05	0.00012	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.19e-05	0.000118	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SOCS3—atherosclerosis	1.17e-05	0.000116	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL6—atherosclerosis	1.16e-05	0.000116	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MMP3—atherosclerosis	1.13e-05	0.000112	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IGF2—atherosclerosis	1.12e-05	0.000111	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.1e-05	0.000109	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—APOB—atherosclerosis	1.09e-05	0.000108	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CXCL8—atherosclerosis	1.08e-05	0.000107	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKT1—atherosclerosis	1.07e-05	0.000107	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EDN1—atherosclerosis	1.07e-05	0.000106	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCL5—atherosclerosis	1.06e-05	0.000106	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—APOA2—atherosclerosis	1.04e-05	0.000104	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.04e-05	0.000104	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.04e-05	0.000104	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.04e-05	0.000104	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LPL—atherosclerosis	1.04e-05	0.000103	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.03e-05	0.000102	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PRKCG—atherosclerosis	1.01e-05	0.0001	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LPA—atherosclerosis	9.96e-06	9.89e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SPP1—atherosclerosis	9.84e-06	9.78e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CXCL8—atherosclerosis	9.8e-06	9.74e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—BGN—atherosclerosis	9.65e-06	9.58e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—APOA5—atherosclerosis	9.55e-06	9.48e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	9.19e-06	9.13e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PDGFB—atherosclerosis	9.11e-06	9.05e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AGT—atherosclerosis	8.89e-06	8.83e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ALOX5—atherosclerosis	8.88e-06	8.82e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LEP—atherosclerosis	8.71e-06	8.65e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—APOE—atherosclerosis	8.71e-06	8.65e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CAV1—atherosclerosis	8.63e-06	8.57e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—APOA1—atherosclerosis	8.61e-06	8.55e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ESR1—atherosclerosis	8.32e-06	8.26e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—F2—atherosclerosis	8.22e-06	8.16e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NAMPT—atherosclerosis	7.96e-06	7.91e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LIPC—atherosclerosis	7.91e-06	7.86e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—APOC3—atherosclerosis	7.86e-06	7.81e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CG—atherosclerosis	7.86e-06	7.81e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LDLR—atherosclerosis	7.82e-06	7.76e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CETP—atherosclerosis	7.63e-06	7.58e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	7.53e-06	7.48e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—INS—atherosclerosis	7.44e-06	7.39e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCL2—atherosclerosis	7.32e-06	7.27e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SCARB1—atherosclerosis	7.31e-06	7.26e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IGF1—atherosclerosis	7.2e-06	7.15e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HMGCR—atherosclerosis	6.9e-06	6.86e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	6.84e-06	6.79e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NOS3—atherosclerosis	6.53e-06	6.48e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCA1—atherosclerosis	6.15e-06	6.11e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCL8—atherosclerosis	5.79e-06	5.75e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	5.59e-06	5.56e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL6—atherosclerosis	5.51e-06	5.47e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HMOX1—atherosclerosis	5.28e-06	5.24e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MMP9—atherosclerosis	5.24e-06	5.2e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NFKB1—atherosclerosis	5.18e-06	5.15e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAPK8—atherosclerosis	5.09e-06	5.06e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AKT1—atherosclerosis	5.08e-06	5.05e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—APOB—atherosclerosis	5.06e-06	5.02e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.92e-06	4.89e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LPL—atherosclerosis	4.83e-06	4.8e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GPX1—atherosclerosis	4.71e-06	4.68e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VEGFA—atherosclerosis	4.7e-06	4.67e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—STAT3—atherosclerosis	4.66e-06	4.62e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CD36—atherosclerosis	4.59e-06	4.56e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAPK3—atherosclerosis	4.45e-06	4.42e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MTHFR—atherosclerosis	4.35e-06	4.32e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TGFB1—atherosclerosis	4.32e-06	4.29e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PPARA—atherosclerosis	4.27e-06	4.24e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AGT—atherosclerosis	4.13e-06	4.1e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—APOE—atherosclerosis	4.05e-06	4.02e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CAV1—atherosclerosis	4.01e-06	3.98e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—APOA1—atherosclerosis	4e-06	3.97e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.65e-06	3.63e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PPARG—atherosclerosis	3.53e-06	3.5e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—INS—atherosclerosis	3.46e-06	3.43e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL6—atherosclerosis	3.25e-06	3.23e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ALB—atherosclerosis	3.17e-06	3.15e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NOS3—atherosclerosis	3.03e-06	3.01e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKT1—atherosclerosis	3e-06	2.98e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.77e-06	2.75e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKT1—atherosclerosis	1.39e-06	1.38e-05	CbGpPWpGaD
